<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30066">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856517</url>
  </required_header>
  <id_info>
    <org_study_id>2011PPRC01TURC</org_study_id>
    <nct_id>NCT01856517</nct_id>
  </id_info>
  <brief_title>Upregulation of Alpha-1 Receptors Upon Septic Shock?</brief_title>
  <acronym>CATACHOC</acronym>
  <official_title>Up Regulation of Alpha-1 Receptors Upon Septic Shock ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hallmarks of septic shock are hypovolemia and reduced pressor response to endogenous
      noradrenaline. The working hypothesis is that the higher the plasma concentration of
      endogenous noradrenaline will be, the lower the pressor response to exogenous noradrenaline
      will be. This will be tested in patients presenting with septic shock, following state of
      the art management (including repeated assessment of vena cava diameter and compliance, and
      response to dynamic indices of loading) following placebo vs clonidine administration (1
      mcg.kg-1.h-1 over 24 h without bolus) and administration of increasing doses of
      noradrenaline (1 mcg, 2 mcg, etc. up to a delta systolic blood pressure circa 25-30 mm Hg).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>change in pressor response to exogenous noradrenaline</measure>
    <time_frame>0 and 24 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>bolus of exogenous noradrenaline (1 mcg and up) are administered to the patient to evoke an  increase in delta systolic blood pressure by 25-30 mm Hg. Administration of increasing dose of noradrenaline is stopped as soon as delta systolic blood pressure has reached 25-30 mm Hg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in heart rate response to increasing doses of dobutamine (100 mcg and up) to evoke an increase in heart rate up to 20 beats per min.</measure>
    <time_frame>0 and 24 h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline administration over 24 h following full optimization of patient according to current guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <arm_group_label>clonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients presenting to the CCU with septic shock : SBP&lt;90 mm Hg refractory to volume
             load (&gt;30 ml.kg-1 within 6 h before inclusion) thus in need administration of
             noradrenaline for &gt;1 h (0.1 mcg.kg-1.h-1 i.e. &gt;0.5 mg.h-1/70 kg) to maintain mean
             BP&gt;65 mm Hg.

          -  criteria for sepsis :temperature&gt;38.5 or &lt;36°C ; WBC&gt;12 000 or &lt;4000/ml ; tachypnea
             (&gt;20 cycles par min) or mechanical ventilation ; tachycardia : &gt;90 bpmin

          -  written informed consent by the patient or next of kin or signature by the
             investigators of the form &quot;emergency inclusion&quot;

        Exclusion Criteria:

          -  age&lt;18 ans

          -  pregnancy

          -  mental illness making informed consent impossible

          -  Absence of consent as signed by the patient or next of kin or signature of &quot;emergency
             inclusion form&quot;

          -  individual without social security coverage or participating in another biomedical
             research

          -  Contre-indications to  clonidine (uncorrected hypovolemia, sick sinus syndrom, III
             grade AV block)

          -  HR&lt;70 bp/min

          -  pre-exitus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Dardare, MD</last_name>
    <phone>33 4 72 36 67 43</phone>
    <email>eric.dardare@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Critical Care Unit, Hopital Desgenettes</name>
      <address>
        <city>Lyon</city>
        <zip>69275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Dardare, MD</last_name>
      <phone>33 4 72 36 67 43</phone>
      <email>eric.dardare@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eric Dardare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Quintin, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>April 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Direction Centrale du Service de Santé des Armées</investigator_affiliation>
    <investigator_full_name>Eric Dardare</investigator_full_name>
    <investigator_title>MD attending physician</investigator_title>
  </responsible_party>
  <keyword>pressor response</keyword>
  <keyword>chronotropic response</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
